A phase III study of Calmangafodipir (PledOx®) in patients with metastatic colorectal cancer
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Calmangafodipir (Primary)
- Indications Chemotherapy-induced damage
- Focus Registrational; Therapeutic Use
- Acronyms POLAR-M
- 01 Dec 2017 According to a PledPharma media release,based on the data form Phase1 (290697) trial, an expansion of including asian patients for the phase III clinical programm is depended.
- 16 Nov 2017 According to a PledPharma media release, the company intends to initiate the Phase III study before year end 2017 and to have first patient in by early 2018.
- 20 Oct 2016 According to a PledPharma media release, top-line results from the study are anticipated in the year 2020.